NCT00212108

A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: National University Hospital, Singapore · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

EGFR and COX-2 are involved in tumorigenesis, angiogenesis and metastases and are frequently over expressed in NPC.COX-2 and EGFR inhibitors are active in NPC.There is synergistic action between COX-2 and EGFR inhibitors. Study hypothesis: Celecoxib and gefitinib can reduce angiogenesis and induce anti-tumorigenicity in patients with nasopharngeal cancer.

Conditions

• Nasopharyngeal Carcinoma

Interventions

Type	Name	Description
DRUG	celecoxib, gefitinib	The dose of ZD1839 to be administered is 250mg. ZD1839 will be taken once daily in the morning at approximately the same time each day. If the patient inadvertently did not take the dose in the morning, the patient may take that dose anytime up to 10pm that same day. The daily treatment will be resumed the next day at the scheduled morning dose. Celecoxib will be administered at 400 mg bd.

Timeline

• Start date: 2003-11-01
• Primary completion: 2007-03-01
• Completion: 2009-01-01
• First posted: 2005-09-21
• Last updated: 2012-04-02

Locations

1 site across 1 country: Singapore